Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
137 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
CABA, Argentina
- Research Site
Ciudad Autónoma Buenos Aires, Argentina
- Research Site
Ciudad de Buenos Aires, Argentina
- Research Site
Ciudad de Buenos Aires, Argentina
- Research Site
La Plata, Argentina
- Research Site
Rosario, Argentina
- Research Site
San Miguel de Tucumán, Argentina
- Research Site
Box Hill, Australia
- Research Site
Macquarie University, Australia
- Research Site
Belo Horizonte, Brazil
- Research Site
Brasília, Brazil
- Research Site
Cachoeiro de Itapemirim, Brazil
- Research Site
Criciúma, Brazil
- Research Site
Curitiba, Brazil
- Research Site
Florianópolis, Brazil
- Research Site
Fortaleza, Brazil
- Research Site
Natal, Brazil
- Research Site
Pelotas, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Porto Alegre, Brazil
- Research Site
Rio de Janeiro, Brazil
- Research Site
Salvador, Brazil
- Research Site
São Jose Do Rio Preto, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
São Paulo, Brazil
- Research Site
Vitória, Brazil
- Research Site
Calgary, Alberta, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Montreal, Quebec, Canada
- Research Site
Providencia, Chile
- Research Site
Santiago, Chile
- Research Site
Santiago, Chile
- Research Site
Temuco, Chile
- Research Site
Beijing, China
- Research Site
Changsha, China
- Research Site
Changsha, China
- Research Site
Chongqing, China
- Research Site
Harbin, China
- Research Site
Jinan, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Oct 2021
- Primary completion
- 31 Dec 2025
- Completion
- 1 Feb 2027
- Last update posted
- 22 May 2026
- Registered enrollment
- 148
- Registry id
- NCT05043090
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.